BOLT

0.3535

0.71% 0.0025

Handel nachbörslich: .35 -0.0035 -0.99%

Bolt Biotherapeutics Inc (BOLT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.351

Offen:

$0.359

24-Stunden-Volumen:

23,213

Relative Volume:

0.20

Marktkapitalisierung:

$14.95M

Einnahmen:

$7.88M

Nettoeinkommen (Verlust:

$-69.20M

KGV:

-0.1932

EPS:

-1.83

Netto-Cashflow:

$-69.73M

1W Leistung:

-9.36%

1M Leistung:

-11.85%

6M Leistung:

-46.32%

1J Leistung:

-67.86%

1-Tages-Spanne:

$0.35

$0.37

1-Wochen-Bereich:

$0.3407

$0.4048

52-Wochen-Spanne:

$0.30

$1.335

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Firmenname

Bolt Biotherapeutics Inc

Sektor

Healthcare (1178)

Branche

Biotechnology (677)

Telefon

650-665-9295

Adresse

900 CHESAPEAKE DRIVE, REDWOOD CITY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

BOLT's Discussions on Twitter

Vergleichen Sie BOLT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BOLT Bolt Biotherapeutics Inc	0.3535	14.95M	7.88M	-69.20M	-69.73M	-1.83
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-03-02	Eingeleitet	Guggenheim	Buy
2021-03-02	Eingeleitet	Morgan Stanley	Overweight
2021-03-02	Eingeleitet	SVB Leerink	Outperform
2021-03-02	Eingeleitet	Stifel	Buy

Bolt Biotherapeutics Inc Aktie (BOLT) Neueste Nachrichten

May 01, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia

May 01, 2025

Apr 30, 2025

Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus

Apr 30, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times

Apr 30, 2025

New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan

Apr 30, 2025

Apr 29, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India

Apr 29, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus

Apr 25, 2025

Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India

Apr 25, 2025

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Apr 25, 2025

Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan

Apr 25, 2025

Apr 17, 2025

Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 16, 2025

Bolt Biotherapeutics modifies quorum requirements - Investing.com

Apr 16, 2025

Apr 12, 2025

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com

Apr 12, 2025

Apr 10, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 10, 2025

Apr 08, 2025

Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire

Apr 08, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 08, 2025

Apr 07, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire

Apr 07, 2025

Apr 04, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK

Apr 04, 2025

Apr 03, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

Mar 29, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock By Investing.com - Investing.com Australia

Mar 26, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock - Investing.com India

Mar 26, 2025

Bolt Biotherapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Mar 26, 2025